The concept of antibody–drug conjugations (ADCs) can be tracked back to the early 20th
century when the renowned immunologist, Paul Ehrlich, proposed the idea of a “magic …

Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an
oncogenic driver in a subset of breast cancers and the development of HER2 directed …

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is
overexpressed in 20–30% of breast cancers and is associated with poor prognosis and …

The recent decade has witnessed a vigorous prosper of antibody-drug conjugates (ADCs) in
solid tumors including breast cancer. Integrating the specificity of monoclonal antibodies and …

Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that
exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic …

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

Abstract Antibody–drug conjugates (ADCs)—a groundbreaking class of agents for targeted
oncological therapies—consist of monoclonal antibodies with strong antigenic specificity …

ABSTRACT Introduction Antibody–drug conjugates (ADCs) are a relatively new class of anti-
cancer therapies approved for a number of malignancies, including breast cancer. Their …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …